Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupFLT3 mutationHigh riskMDS with elevated blasts -2ICD10C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHLeukemia, Monocytic, AcuteLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSequenceAMLSG 31-19/HOVON 501DAUN60/CYTA200/MDST50, AML Ind. (PID1079) -|- Cons. (PID1080) -|- maint. (PID1081)ChemotherapyChemo-substanceAzacitidineCytarabineDaunorubicinGlasdegibLenalidomideMelphalanMidostaurinVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinGlasdegibLenalidomideMelphalanMidostaurinVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinGlasdegibLenalidomideMelphalanMidostaurinVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinGlasdegibLenalidomideMelphalanMidostaurinVenetoclaxNo. Substances123 RadiotherapySupportive therapySupportive substanceAllopurinolBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFilgrastimGranisetronPegfilgrastimPosaconazoleSupportive substanceAllopurinolBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFilgrastimGranisetronPegfilgrastimPosaconazoleSupportive substanceAllopurinolBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFilgrastimGranisetronPegfilgrastimPosaconazoleSupportive substanceAllopurinolBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFilgrastimGranisetronPegfilgrastimPosaconazoleNo. Substances12356Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityLow doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseConsolidationInductionMaintenanceTherapy intentioncurativecurative or palliativepalliativeRisksAnemia Hb below 8g/dlAstheniaColitisDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHyperbilirubinemiaHyperglycemiaHypokalemiaHyponatremiaHypophosphatemiaIncrease AminotransferasesInfectionsNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorCortes JECraddock CDöhner HLübbert MPlatzbecker USchroeder TStone RStratmann JDiseaseAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2de-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)neudiagnostizierte AML, Erhaltung bei Patienten in kompletter Remission, FLT3-Mutation, ErstlinieNeu diagnostizierte AML oder MDS mit Blastenüberschuss-2, ECOG 0-2OriginCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialDana-Farber Cancer Institute, Boston MADivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyUlm University Hospital, Germany, AMLSG 31-19/HOVON 501University of Birmingham, Birmingham, United KingdomUniversity of Texas, MD Anderson Cancer Center, Houston, USAProtocols in Revision 12 protocols foundAzacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation, Variant 1. (PID2320 V1.0)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation. (PID2327 V1.0)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674 V1.0)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735 V1.1)Midostaurin 50, Acute Myeloid Leukemia, maintenance (PID1081 V1.1)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction II, over 60 years of age (PID3142 V1.0)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, consolidation, over 60 years of age (PID3144 V1.0)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1500 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Consolidation, under 60 years of age (PID3143 V1.0)Study-AMLSG 31-19/HOVON 501 - Daunorubicin 60 / Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction II, under 60 years of age (PID3141 V1.0)Study-AMLSG 31-19/HOVON 501 - Daunorubicin 60 / Cytarabine 200 / Venetoclax (100/200/400), Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction I (PID3140 V1.0)
